Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

CERO · OTC · United States · Biological Products, (No Diagnostic Substances)

CERO THERAPEUTICS HOLDINGS, INC.

South San Francisco, CA · Fiscal year ends in December · Figures in USD

In shortCERO THERAPEUTICS HOLDINGS, INC. is loss-making.

Financial health

Weak

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

Profitability0

Operating marginShare of each sale left after running the business, before interest and tax.	–	n/a
Net marginShare of each sale left as profit after every cost, interest and tax.	–	n/a
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	–	0/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	–	n/a

Weight in the score: 25%

Balance sheet0

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	0.30×	0/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	–	0/100
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	–	n/a
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	–	n/a
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	–	n/a

Weight in the score: 25%

Cash generation0

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	–	n/a
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	–	n/a
Years with positive free cash flow (last 5)	0 of 3	0/100

Weight in the score: 20%

Stability0
Profitable years (last 5) 0 of 3 0/100
Years of revenue decline (last 5) – n/a
Revenue growth volatility – n/a
Operating margin volatility – n/a
Weight in the score: 20%
Growth–
Revenue growth, 3-year average – n/a
EPS growth, 3-year average – n/a
Weight in the score: 10%

Profitable years (last 5)	0 of 3	0/100
Years of revenue decline (last 5)	–	n/a
Revenue growth volatility	–	n/a
Operating margin volatility	–	n/a

Revenue growth, 3-year average	–	n/a
EPS growth, 3-year average	–	n/a

Fiscal year 2025 · change vs prior year

Annual figures as reported. Hover a bar or point for the exact value.

RevenueNet income

No data reported.

The last 3 fiscal years from the company's annual reports.

USD millions; negative values in parentheses.

Fiscal year	FY22	FY23	FY25
Research & development	–	5.3	–
Operating income	(2.9)	(7.7)	–
Interest expense	–	(0.1)	–
Pre-tax income	(0.1)	(2.4)	(20)
Income tax	0.6	0.1	–
Net income	(0.7)	(7.3)	(20)
Diluted EPS	–	−$1,248.64	–
Diluted shares (millions)	–	0	–

The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.

The last 8 quarters of CERO THERAPEUTICS HOLDINGS, INC. are included in the Investor plan. Try free for 7 days →

Not computed: a required balance-sheet item is missing.

Not computed: it needs two consecutive complete years.

CERO THERAPEUTICS HOLDINGS, INC. (CERO) financial health, profit and balance sheet · Scorvest